Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK1D | P48730 | 1/20 | 0.38 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.33 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.31 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.31 |
| ▸ | BRAF | P15056 | 1/20 | 0.31 |
| ▸ | TRPM5 | Q9NZQ8 | 1/20 | 0.31 |
| ▸ | PRKACA | P17612 | 1/20 | 0.30 |
| ▸ | PRKACG | P22612 | 1/20 | 0.30 |
| ▸ | PRKACB | P22694 | 1/20 | 0.30 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.30 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL38656657 | 0.78 | CHRNB2 (0.37) | KCNH2 | |
| SCHEMBL38655205 | 0.78 | CHRNB2 (0.37) | KCNH2 | |
| Hydrochloric Acid SCHEMBL38655684 | 0.77 | CHRNB2 (0.36) | KCNH2 | |
| Hydrochloric Acid SCHEMBL38658223 | 0.77 | CHRNB2 (0.36) | KCNH2 | |
| SCHEMBL38655227 | 0.74 | MAP4K4 (0.41) | CSNK1DCSNK1EKCNH2 | |
| SCHEMBL24540984 | 0.72 | CSNK1D (0.40) | CSNK1DCSNK1EKCNH2MALT1PRKACA | |
| SCHEMBL11142305 | 0.71 | CSNK1D (0.36) | CSNK1DCSNK1EKCNH2PRKACAPRKACG | |
| SCHEMBL38656215 | 0.71 | SGK1 (0.41) | CSNK1DCSNK1EKCNH2ACVR1 | |
| SCHEMBL31444533 | 0.70 | CSNK1D (0.36) | CSNK1DCSNK1EKCNH2NR1I2BRAF | |
| SCHEMBL11148032 | 0.70 | CSNK1D (0.34) | CSNK1DCSNK1EKCNH2ACVR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026102082-A1 | ALKYLPHENYL SUBSTITUTED COMPOUNDS, COMPOSITIONS AND METHODS OF USE | DEEP APPLE THERAPEUTICS, INC. (US) | 2026-05-15 | — | — | WO | disclosed |
| US-20260132119-A1 | Alkylphenyl Substituted Compounds, Compositions and Methods of Use | DEEP APPLE THERAPEUTICS, INC. (US) | 2026-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260132119-A1 | Alkylphenyl Substituted Compounds, Compositions and Methods of Use | GIPR, MC2R, GRPR | CSNK1D 526/4885CSNK1E 490/4885KCNH2 945/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.